Terug
Dagbereik
€ 2,58
€ 3,56
52-Weeksbereik
€ 0,83
€ 4,74
Volume
1.000
50D / 200D Gem.
€ 2,91
/
€ 3,49
Vorige Slotkoers
€ 2,58
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,9 | 0,4 |
| P/B | 0,4 | 2,9 |
| ROE % | 14,2 | 3,7 |
| Net Margin % | 23,0 | 3,9 |
| Rev Growth 5Y % | 13,0 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 1,39
€ 1,09 – € 1,86
|
12 B | 1 |
| FY2026 |
€ 1,30
€ 1,02 – € 1,73
|
11 B | 1 |
Belangrijkste Punten
Revenue grew 12,99% annually over 5 years — strong growth
Earnings grew 34,93% over the past year
ROE of 14,19% — decent returns on equity
Net margin of 22,95% shows strong profitability
Debt/Equity of 0,23 — conservative balance sheet
Generating 2,24B in free cash flow
Groei
Revenue Growth (5Y)
12,99%
Revenue (1Y)16,53%
Earnings (1Y)34,93%
FCF Growth (3Y)36,19%
Kwaliteit
Return on Equity
14,19%
ROIC10,79%
Net Margin22,95%
Op. Margin29,99%
Veiligheid
Debt / Equity
0,23
Current Ratio1,71
Interest Coverage14,31
Waardering
P/E Ratio
2,91
P/B Ratio0,39
EV/EBITDA2,79
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 16,53% | Revenue Growth (3Y) | 15,23% |
| Earnings Growth (1Y) | 34,93% | Earnings Growth (3Y) | 4,46% |
| Revenue Growth (5Y) | 12,99% | Earnings Growth (5Y) | 25,76% |
| Profitability | |||
| Revenue (TTM) | 9,11B | Net Income (TTM) | 2,09B |
| ROE | 14,19% | ROA | 8,63% |
| Gross Margin | 85,95% | Operating Margin | 29,99% |
| Net Margin | 22,95% | Free Cash Flow (TTM) | 2,24B |
| ROIC | 10,79% | FCF Growth (3Y) | 36,19% |
| Safety | |||
| Debt / Equity | 0,23 | Current Ratio | 1,71 |
| Interest Coverage | 14,31 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 2,91 | P/B Ratio | 0,39 |
| P/S Ratio | 0,67 | PEG Ratio | 0,19 |
| EV/EBITDA | 2,79 | Dividend Yield | 0,04% |
| Market Cap | 6,09B | Enterprise Value | 7,62B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 9,11B | 7,82B | 6,86B | 6,38B | 5,59B |
| Net Income | 2,09B | 1,55B | 1,92B | 1,65B | 835,79M |
| EPS (Diluted) | 0,85 | 0,62 | 0,74 | 0,62 | 0,33 |
| Gross Profit | 7,83B | 6,64B | 5,67B | 5,28B | 4,52B |
| Operating Income | 2,73B | 2,46B | 2,07B | 1,83B | 1,46B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 24,21B | 23,63B | 21,99B | 19,21B | 17,68B |
| Total Liabilities | 6,18B | 7,11B | 6,59B | 4,55B | 4,58B |
| Shareholders' Equity | 15,44B | 14,03B | 12,96B | 12,23B | 10,69B |
| Total Debt | 3,55B | 4,84B | 4,52B | 2,63B | 2,91B |
| Cash & Equivalents | 2,02B | 2,69B | 2,15B | 2,80B | 3,09B |
| Current Assets | 9,35B | 9,19B | 9,76B | 7,79B | 6,68B |
| Current Liabilities | 5,46B | 3,73B | 1,79B | 1,42B | 1,45B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026